Patient-Derived Xenograft / PDX Model Market Worth $839 million | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251 Browse in-depth TOC on "Patient-Derived Xenograft / PDX Model Market" 130 - Tables 40 - Figures 180 - Pages Patient-Derived Xenograft / PDX Model Market Scope:   Mouse model type accounted for the largest share of the patient-derived xenograft/ PDX model market...

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251

Browse in-depth TOC on "Patient-Derived Xenograft / PDX Model Market"

130 - Tables
40 - Figures
180 - Pages

Patient-Derived Xenograft / PDX Model Market Scope:

 

Mouse model type accounted for the largest share of the patient-derived xenograft/ PDX model market.

Among the types, the patient-derived xenograft/ PDX model market is segmented into mouse model, and rat model. In 2023, the mouse model segment accounted for the largest share of the patient-derived xenograft/ PDX model market. Growth in this market segment can be attributed to biological similarities of the mice model with human tumors, and the availability of immunodeficient strains is expected to form the largest share segment in the patient derived xenograft/ PDX model market.

The respiratory tumor type segment is the fastest-growing segment of the patient derived xenograft/ PDX model market.

In 2023, the respiratory tumor type segment accounted for the fastest-growing share of the tumor type segment of the patient derived xenograft/ PDX model market. Market growth can largely be attributed to the rising prevalence of lung cancer. The market is also driven by increasing focus on the drug development of respiratory tumor models after the COVID-19 pandemic.

Asia Pacific: The fastest-growing region in the patient derived xenograft/ PDX model market.

The Asia Pacific patient derived xenograft/ PDX model market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of precision medicine and a rise in the number of drug development processes. The Asian market has also garnered significant attention from global players due to the increasing pharmaceutical R&D spending, and the growing trend of outsourcing drug discovery services.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251

Patient-Derived Xenograft / PDX Model Market Dynamics:

Drivers:

Restraints:

Opportunities:

Challenge:

Key Market Players of Patient-Derived Xenograft / PDX Model Industry:

The market for patient-derived xenograft/ PDX models is highly fragmented, with key players strategizing to capture a majority of the market. Prominent players in the market are JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US),  EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).

Recent Developments:

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=121598251

Patient-Derived Xenograft / PDX Model Market Advantages:

Related Reports:

Mice Model Market - Global Forecasts To 2028

Humanized Mouse and Rat Model Market - Global Forecasts to 2028

CRO Services Market - Global Forecasts to 2028

Life Science Instrumentation Market - Global Forecasts to 2028

In Vitro Toxicology Testing Market - Global Forecasts to 2027

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/patient-derived-xenograft-model-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/patient-derived-xenograft-model.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/patient-derived-xenograft--pdx-model-market-worth-839-million--marketsandmarkets-301960314.html